Related Experiment Video

Updated: May 18, 2026

Differentiation of Functional Osteoclasts from Human Peripheral Blood CD14+ Monocytes
11:52

Differentiation of Functional Osteoclasts from Human Peripheral Blood CD14+ Monocytes

Published on: January 27, 2023

Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases

Junichi Kikuta1, Masaru Ishii

  • 1Laboratory of Cellular Dynamics, Immunology Frontier Research Center, Osaka University, 3-1 Yamada-oka, Suita, Osaka, Japan.

Rheumatology (Oxford, England)
|October 2, 2012
PubMed

Insights

Rheumatoid arthritis (RA) causes bone destruction via increased osteoclast activity. This review explores osteoclast mechanisms and novel therapies targeting bone loss in RA patients.

Area of Science:

  • Immunology
  • Rheumatology
  • Cell Biology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and bone destruction.
  • Current RA treatments do not prevent bone loss, a severe complication.
  • Enhanced osteoclast activity is a key factor in RA-associated bone destruction.

Purpose of the Study:

  • To review the mechanisms of osteoclast activity in RA.
  • To discuss novel osteoclast-targeted therapies for RA bone destruction.

Main Methods:

  • Literature review of osteoclast differentiation, migration, and function.
  • Analysis of cytokine signaling (M-CSF, RANK ligand) in osteoclastogenesis.
  • Exploration of emerging therapeutic strategies targeting osteoclasts.

Main Results:

  • Osteoclasts are critical for bone resorption in RA.
  • Understanding osteoclast dynamics (migration, differentiation, function) is crucial.
  • Novel therapeutic targets are emerging to inhibit osteoclast activity.

Conclusions:

  • Targeting osteoclast activity offers a promising strategy to prevent bone destruction in RA.
  • Further research into osteoclast-targeted therapies could significantly improve RA patient outcomes.

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...